Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica

@inproceedings{Araki2014EfficacyOT,
  title={Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica},
  author={Manabu Araki and Takako Matsuoka and Katsuichi Miyamoto and Susumu Kusunoki and Tomoko Okamoto and Miho Murata and Sachiko Miyake and Toshimasa Aranami and Takashi Yamamura},
  booktitle={Neurology},
  year={2014}
}
OBJECTIVE To evaluate the safety and efficacy of a humanized anti-interleukin-6 receptor antibody, tocilizumab (TCZ), in patients with neuromyelitis optica (NMO). METHODS Seven patients with anti-aquaporin-4 antibody (AQP4-Ab)-positive NMO or NMO spectrum disorders were recruited on the basis of their limited responsiveness to their current treatment. They were given a monthly injection of TCZ (8 mg/kg) with their current therapy for a year. We evaluated the annualized relapse rate, the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study

  • M Araki, T Matsuoka, K Miyamoto
  • Neurology
  • 2014
2 Excerpts

Reversal of cancer pain through anti-interleukin-6 treatment

  • M Andratsch, N Mair, CE Constantin
  • J Neurosci 2009;29:13473–13483. Neurology
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…